阿扎胞苷联合维奈克拉治疗老年髓系白血病的疗效评价

Evaluation of the Therapeutic Effect of Azacytidine Combined with Vene⁃toclax in the Treatment of Elderly Myeloid Leukemia

目的探讨老年髓系白血病以阿扎胞苷+维奈克拉进行治疗的可行性。方法非随机选取2019年8月—2023年8月桂平市人民医院血液内科收治的80例老年髓系白血病患者,按治疗方法不同分为两组:对照组(n=40,给予阿扎胞苷单一用药治疗)与研究组(n=40,给予阿扎胞苷与维奈克拉联合用药治疗),对比两组治疗有效率、血生化指标、不良反应发生率。结果研究组治疗有效率(90.00%)较对照组(72.50%)高,差异有统计学意义(χ^(2)=4.021,P<0.05)。研究组血小板计数、白细胞计数、血红蛋白浓度较对照组高,骨髓原始细胞比例较对照组低,差异有统计学意义(P均<0.05);研究组不良反应发生率(5.00%)较对照组(20.00%)低,差异有统计学意义(χ^(2)=4.114,P<0.05)。结论在老年髓系白血病患者采取阿扎胞苷与维奈克拉联合用药治疗可改善其血生化指标,减少不良反应的发生,可提高治疗效果。

Objective To investigate the feasibility of azacitidine plus Venacela in the treatment of elderly myeloid leukemia.Methods From August 2019 to August 2023,a total of 80 patients with elderly myeloid leukemia in the De-partment of Hematology,Guiping People's Hospital were unrandomly selected.They were divided into two groups:the control group(n=40,treated with azacitidine alone)and the study group(n=40,treated with azacytidine combined with venetoclax)by difference treatment.The effective rate,blood biochemical index,adverse reaction rate and quality of life score were compared.Results The effective rate of treatment in the study group was 90.00%,higher than that in the control group(72.50%),the difference was statistically significant(χ^(2)=4.021,P<0.05).The platelet count,white blood cell count,and hemoglobin concentration in the study group were higher than those in the control group,and the proportion of bone marrow primitive cells was lower than those in the control group,the differences were statistically significant(all P<0.05).The incidence of adverse reactions in the study group was 5.00%,lower than that in the con-trol group(20.00%),the difference was statistically significant(χ^(2)=4.114,P<0.05).Conclusion In elderly patients with myeloid leukemia,the combination therapy of azacitidine and vinacrine can improve their blood biochemical indica-tors,reduce the occurrence of adverse reactions,and improve treatment effectiveness.